Senti Biosciences(SNTI) - 2024 Q3 - Quarterly Results
Senti Biosciences(SNTI)2024-11-14 21:32
Senti Bio Announces Third Quarter 2024 Results and Recent Pipeline and Corporate Highlights – Enrollment continues in Phase 1 clinical trial of SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including AML; initial clinical data expected in Q4 2024 – SOUTH SAN FRANCISCO, Calif., November 14, 2024 -- Senti Biosciences, Inc. (Nasdaq: SNTI) ("Senti Bio" or the "Company"), a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit pl ...